| Name | Title | Contact Details |
|---|
Cagent Vascular is leading the way for next generation technology for vessel dilatation.
Quality Transcription is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
To improve the lives of those impacted by disease and disability. To provide accessible, accurate, and reliable analysis in a way that facilitates and adapts to our clients` needs to progress their clinical trials at the fastest possible pace. While our technology makes us unique, it is our people who make us special. Our teams utilize creativity, flexibility and expertise to design personalized solutions to meet our customers` goals and objectives. But what truly sets us apart is the internal motivation of our employees and the pride they take in helping customers affect the lives of those in need.
Waterloo Healthcare is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.